CSTL Chief Commercial Officer W Sells $111K of Stock

Juvenal Tobin, Chief Commercial Officer of Castle Biosciences, Inc. (CSTL on NasdaqGM), sold 3,288 shares on October 12, 2026, for a total of $110,608.32. This transaction was part of a planned sale.

Inside Juvenal Tobin's Trade

Tobin sold his shares at an average price of $33.64 each. This sale comes as the stock has been trading below its 50-day moving average, which is currently at $33.51.

Other Institutional Activity in Castle Biosciences

Blackrock Inc. owns 3,291,963 shares of Castle Biosciences, worth about $105.2 million, after increasing its stake by 309,032 shares. RTW Investments LP holds 2,778,335 shares valued at roughly $88.8 million, with a slight increase of 20,135 shares. Vanguard Capital Management LLC has 1,226,497 shares worth approximately $39.2 million, after adding 48,985 shares. Acadian Asset Management increased its holdings by 434,215 shares, totaling 918,668 shares valued at about $29.4 million.

Castle Biosciences, Inc. Stock Down 5.0%

As of October 16, 2026, Castle Biosciences traded recently around $32.11, which is 27.5% below its 52-week high of $44.28. The stock is currently below its 50-day moving average by 4.2% but remains above its 52-week low of $17.72 by 81.2%.

Recent Earnings

Castle Biosciences reported trailing twelve-month revenue of $357.3 million, with a revenue growth of 20.1% year-over-year. The company had a net margin of -5.4% and a return on equity of -4.2%. The next earnings report is scheduled for November 5, 2026.

Insider Buying and Selling at Castle Biosciences, Inc.

Earlier on September 30, 2026, Tobin sold 6,577 shares, valued at $232,128, while on October 1, 2026, Kristen Oelschlager, the Chief Operating Officer, sold 4,153 shares for about $149,318. CEO Derek Maetzold also sold 14,496 shares on October 5, 2026, for $515,565 at an average price of $35.57.

Analysts Set New Price Targets

On June 25, 2026, Roth Capital initiated coverage on Castle Biosciences with a Buy rating and a $40 price target. BTIG maintained a Buy rating on August 3, 2026, raising its target from $40 to $44. The consensus among analysts is a strong buy, with a mean price target of $45.22 based on nine analyst opinions.

About Castle Biosciences

Castle Biosciences, Inc. is a molecular diagnostics company based in Friendswood, Texas. It provides test solutions for various dermatologic cancers and other conditions. This insider sale indicates ongoing active management at the company, reflecting the strategic decisions being made by its leaders.

Bottom Line

Watch for the upcoming earnings report on November 5, 2026, to gauge Castle Biosciences' financial health. Tobin's recent sale is part of a broader trend of insider transactions at the company, which may signal varying perspectives on its future performance.